Stock Track | Veracyte Soars 16.73% After-Hours on Strong Q1 Results and Raised Guidance

Stock Track05-06

Veracyte's stock surged 16.73% in after-hours trading following the release of its first-quarter financial results, which significantly exceeded analyst expectations.

The diagnostic company reported quarterly earnings of $0.52 per share, beating the consensus estimate of $0.15 by 246.67%. Revenue for the quarter reached $139.1 million, surpassing estimates of $130 million and representing a 21% year-over-year increase. Net income saw a dramatic rise of 307% to $28.7 million, while adjusted EBITDA increased 73% to $42.8 million.

Veracyte also raised its full-year 2026 guidance, increasing its adjusted EBITDA margin outlook to greater than 26% and projecting total revenue between $582 million and $592 million. The company cited strong performance across its testing portfolio and upcoming product launches as key drivers for the positive outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163656272?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 04:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163656272","market":"sg","top_or_hot":-1,"title":"Stock Track | Veracyte Soars 16.73% After-Hours on Strong Q1 Results and Raised Guidance","media":"Stock Track","content":"<p>Veracyte's stock surged 16.73% in after-hours trading following the release of its first-quarter financial results, which significantly exceeded analyst expectations.</p><p>The diagnostic company reported quarterly earnings of $0.52 per share, beating the consensus estimate of $0.15 by 246.67%. Revenue for the quarter reached $139.1 million, surpassing estimates of $130 million and representing a 21% year-over-year increase. Net income saw a dramatic rise of 307% to $28.7 million, while adjusted EBITDA increased 73% to $42.8 million.</p><p>Veracyte also raised its full-year 2026 guidance, increasing its adjusted EBITDA margin outlook to greater than 26% and projecting total revenue between $582 million and $592 million. The company cited strong performance across its testing portfolio and upcoming product launches as key drivers for the positive outlook.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Veracyte Soars 16.73% After-Hours on Strong Q1 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Veracyte Soars 16.73% After-Hours on Strong Q1 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 04:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Veracyte's stock surged 16.73% in after-hours trading following the release of its first-quarter financial results, which significantly exceeded analyst expectations.</p><p>The diagnostic company reported quarterly earnings of $0.52 per share, beating the consensus estimate of $0.15 by 246.67%. Revenue for the quarter reached $139.1 million, surpassing estimates of $130 million and representing a 21% year-over-year increase. Net income saw a dramatic rise of 307% to $28.7 million, while adjusted EBITDA increased 73% to $42.8 million.</p><p>Veracyte also raised its full-year 2026 guidance, increasing its adjusted EBITDA margin outlook to greater than 26% and projecting total revenue between $582 million and $592 million. The company cited strong performance across its testing portfolio and upcoming product launches as key drivers for the positive outlook.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCYT","symbol_name":"Veracyte Inc","start_time":0,"source_url":"","article_id":"1163656272","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163656272","pubTimestamp":1778013904,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Veracyte's stock surged 16.73% in after-hours trading following the release of its first-quarter financial results, which significantly exceeded analyst expectations.The diagnostic company reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCYT":"Veracyte Inc"},"translate_title":"个股追踪|Veracyte盘后大涨16.73%，Q1业绩强劲，指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1},"content_text":"Veracyte's stock surged 16.73% in after-hours trading following the release of its first-quarter financial results, which significantly exceeded analyst expectations.The diagnostic company reported quarterly earnings of $0.52 per share, beating the consensus estimate of $0.15 by 246.67%. Revenue for the quarter reached $139.1 million, surpassing estimates of $130 million and representing a 21% year-over-year increase. Net income saw a dramatic rise of 307% to $28.7 million, while adjusted EBITDA increased 73% to $42.8 million.Veracyte also raised its full-year 2026 guidance, increasing its adjusted EBITDA margin outlook to greater than 26% and projecting total revenue between $582 million and $592 million. The company cited strong performance across its testing portfolio and upcoming product launches as key drivers for the positive outlook.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163656272","isCrawlerRequest":true}